the goal of this observational study is to the find the molecular mechanisms underlying the prognosis process of Retinal vein occlusion in patients with retinal vein occlusion . The main question it aims to answer is:

What are the changes in protein in the aqueous humor during treatment in patients who are sensitive to anti-VEGF drug therapy?

Inclusion Criteria:

• Cystic or diffuse edema in the macular area, retinal vein tortuous dilation with hemorrhage
• Optical coherence tomography (OCT) examination showed that the macular area was raised, edema and thickened
• Monocular disease, baseline central retinal thickness (CRT) ≥ 250mm
• Intravitreal injection, laser photocoagulation and blood circulation and blood stasis removal drugs were not treated before surgery
• The patient had normal blood pressure, negative urine protein, normal liver and kidney function, and normal electrocardiogram

Exclusion Criteria:

• Patients with fluorescein fundus angiography (FFA) showing a large area (10 optic disc areas) without perfusion requiring retinal photocoagulation
• Patients with chronic dacryocystitis, glaucoma, cataract, severe proliferative vitreoretinopathy or vitreous hemorrhage, epi macular membrane or macular ischemia, diabetic retinopathy, age-related macular degeneration, ocular trauma and other diseases
• Intravitreal therapy or laser photocoagulation with corticosteroids or anti-VEGF drugs within three months before the study

Patients diagnosed with retinal vein occlusion with macular edema